🎉 M&A multiples are live!
Check it out!

Mabwell Valuation Multiples

Discover revenue and EBITDA valuation multiples for Mabwell and similar public comparables like Vivoryon Therapeutics, Pharming, and Armata Pharmaceuticals.

Mabwell Overview

About Mabwell

Mabwell (Shanghai) Bioscience Co Ltd is engaged in the research and development, production and sales of therapeutic biological products.


Founded

2017

HQ

China
Employees

n/a

Website

mabwell.com

Financials

Last FY Revenue $28.5M

Last FY EBITDA -$121M

EV

$2.6B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Mabwell Financials

See Mabwell valuation multiples based on analyst estimates

Mabwell P&L

In the most recent fiscal year, Mabwell reported revenue of $28.5M and EBITDA of -$121M.

Mabwell expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Mabwell valuation multiples based on analyst estimates
NTM Last FY FY 2026 FY 2027 FY 2028
Revenue XXX $28.5M XXX XXX XXX
Gross Profit XXX $24.4M XXX XXX XXX
Gross Margin XXX 86% XXX XXX XXX
EBITDA XXX -$121M XXX XXX XXX
EBITDA Margin XXX -423% XXX XXX XXX
EBIT XXX -$142M XXX XXX XXX
EBIT Margin XXX -498% XXX XXX XXX
Net Profit XXX -$149M XXX XXX XXX
Net Margin XXX -523% XXX XXX XXX
Net Debt XXX $105M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Mabwell Stock Performance

Mabwell has current market cap of CNY 17.3B (or $2.5B), and EV of CNY 18.3B (or $2.6B).

Market Cap Evolution

Mabwell Stock Data

As of January 19, 2026, Mabwell's stock price is CNY 43 (or $6).

See Mabwell trading valuation data
EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$2.6B $2.5B XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Mabwell Valuation Multiples

Mabwell's trades at 91.8x EV/Revenue multiple, and -21.7x EV/EBITDA.

See valuation multiples for Mabwell and 15K+ public comps

Mabwell Financial Valuation Multiples

As of January 19, 2026, Mabwell has market cap of $2.5B and EV of $2.6B.

Equity research analysts estimate Mabwell's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

Mabwell's P/E ratio is not available.

LTM NTM Last FY FY 2026 FY 2027 FY 2028
Market cap (current) $2.5B XXX $2.5B XXX XXX XXX
EV (current) $2.6B XXX $2.6B XXX XXX XXX
EV/Revenue n/a XXX 91.8x XXX XXX XXX
EV/EBITDA n/a XXX -21.7x XXX XXX XXX
EV/EBIT n/a XXX -18.4x XXX XXX XXX
EV/Gross Profit n/a XXX n/a XXX XXX XXX
P/E n/a XXX -16.6x XXX XXX XXX
EV/FCF n/a XXX -14.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Mabwell Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Mabwell Margins & Growth Rates

Mabwell's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Mabwell's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Mabwell's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Mabwell and other 15K+ public comps

Mabwell Operational Valuation Multiples

LTM NTM Last FY FY 2026 FY 2027 FY 2028
Revenue Growth n/a XXX n/a XXX XXX XXX
EBITDA Margin n/a XXX n/a XXX XXX XXX
EBITDA Growth n/a XXX n/a XXX XXX XXX
Rule of 40 n/a XXX n/a XXX XXX XXX
Bessemer Rule of X XXX XXX n/a XXX XXX XXX
Revenue per Employee XXX XXX n/a XXX XXX XXX
Opex per Employee XXX XXX n/a XXX XXX XXX
S&M Expenses to Revenue XXX XXX 39% XXX XXX XXX
G&A Expenses to Revenue XXX XXX n/a XXX XXX XXX
R&D Expenses to Revenue XXX XXX 392% XXX XXX XXX
Opex to Revenue XXX XXX 584% XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Mabwell Public Comps

See public comps and valuation multiples for Biopharmaceuticals comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
Armata Pharmaceuticals XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Mabwell M&A and Investment Activity

Mabwell acquired  XXX companies to date.

Last acquisition by Mabwell was  XXXXXXXX, XXXXX XXXXX XXXXXX . Mabwell acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Mabwell

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.

Start Free Trial

About Mabwell

When was Mabwell founded? Mabwell was founded in 2017.
Where is Mabwell headquartered? Mabwell is headquartered in China.
Is Mabwell publicy listed? Yes, Mabwell is a public company listed on SHG.
What is the stock symbol of Mabwell? Mabwell trades under 688062 ticker.
When did Mabwell go public? Mabwell went public in 2022.
Who are competitors of Mabwell? Similar companies to Mabwell include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics.
What is the current market cap of Mabwell? Mabwell's current market cap is $2.5B
Is Mabwell profitable? Yes, Mabwell is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.